Although the above-mentioned biochemical and in vitro studies suggest DNMT3A R882 mutations may have unique biological features in comparison with other non-R882 mutations, it is unclear whether MNs with DNMT3A R882 mutations have distinct clinicopathologic features with potential therapeutic implications. Here, DNMT3A is linked to Melnick-Needles syndrome.